A 34-year-old marketing director sits on the edge of an exam table, describing the same story I hear three or four times a week. Standing up triggers a heart rate spike to 130. Crushing fatigue that no amount of sleep resolves. Brain fog thick enough to make her forget her own phone number mid-dial. She has seen a cardiologist, an endocrinologist, and two psychiatrists. The diagnosis she carries: generalized anxiety disorder. The medications she has been prescribed: an SSRI and a benzodiazepine. Neither has touched her symptoms, because anxiety was never the problem.
What the Research Actually Shows
A February 2026 review in ImmunoTargets and Therapy by Blitshteyn, Doherty, and Steinman, researchers at the University of Buffalo and Stanford, makes the case plainly: postural orthostatic tachycardia syndrome (POTS), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and Long COVID are neuroimmune disorders. Not psychiatric. Not psychosomatic. Neuroimmune, with measurable pathology in the brainstem, the immune system, and the autonomic nervous system.
The evidence they compile is specific. Neuroimaging with 7-Tesla MRI reveals structural abnormalities at the dorsolateral medulla, the brainstem region housing vagal nuclei and vestibular pathways. PET scans using protein ligands for activated microglia show increased neuroinflammation in the ventral striatum and dorsal putamen of Long COVID patients. Serum panels reveal elevated IL-1β, IL-6, TNF-α, and G-protein-coupled receptor autoantibodies targeting adrenergic and muscarinic receptors. T-cell exhaustion, NK cell dysfunction, and mast cell hyperactivation appear across all three conditions.
The paper pulls no punches: these disorders belong under the umbrella of neuroimmunology, alongside multiple sclerosis and neuromyelitis optica. The historical parallel matters. What we now call MS was once diagnosed as “hysterical paralysis.” The same dismissal is happening to POTS and ME/CFS patients right now.
Why the Brainstem Matters
The dorsolateral medulla is not some abstract anatomical footnote. It is the control center for heart rate regulation, blood pressure, respiration, gastric motility, and immune modulation via the vagus nerve. When neuroinflammation damages this region, the downstream effects explain nearly every symptom these patients report: orthostatic intolerance, exercise intolerance, GI dysfunction, cognitive impairment, and the relentless fatigue that defines ME/CFS.
Cerebral hypoperfusion compounds the damage. Small penetrating arteries off the vertebrobasilar system may sustain endothelial injury from hypercoagulability and microclots, reducing perfusion to the very structures that regulate autonomic output. Chronic hypoperfusion then triggers further microglial activation through TRPM2 channel pathways, creating a self-reinforcing cycle of inflammation and dysfunction.
This is why patients do not improve with SSRIs or cognitive behavioral therapy. The pathology is structural, not psychological.
The Hidden Contributor: Undiagnosed Sleep Apnea
One factor that often flies under the radar in POTS and ME/CFS patients is obstructive sleep apnea. The overlap is more than coincidental. Sleep apnea drives sympathetic overactivation through repeated episodes of intermittent hypoxia, which elevates catecholamine levels both during sleep and throughout the day. That sympathovagal imbalance persists around the clock.
The downstream effects mirror what we see in POTS: elevated resting heart rate, impaired baroreflex sensitivity, and cognitive dysfunction. Research published in Scientific Reports demonstrated that nocturnal sympathetic overactivity in sleep apnea patients directly correlates with deficits in attention, memory, and executive function. Intermittent hypoxia also triggers neuroinflammation in the hippocampus and cortex, and targets the nucleus tractus solitarius — the same brainstem structure implicated in POTS pathophysiology.
Unrefreshing sleep and daytime fatigue are core diagnostic criteria for ME/CFS, and both are hallmarks of undiagnosed sleep apnea. At The Neurogenesis Project, screening for sleep-disordered breathing is part of every autonomic workup, because treating a patient’s immune dysfunction while their brain is being starved of oxygen eight hours a night is working against yourself.
Nutritional Therapy: Addressing Inflammation at the Source
The neuroinflammatory cascade driving POTS and ME/CFS does not operate in isolation from the rest of the body. Gut-derived inflammation travels the gut-brain axis via vagal afferents, and the same pro-inflammatory cytokines elevated in these patients’ serum are also elevated in their cerebrospinal fluid. A 2024 review in Pain and Therapy found that plant-based, Mediterranean, and whole-food dietary patterns lower systemic inflammation and reduce fatigue in chronic illness. A 2025 systematic review of 809 ME/CFS patients showed that targeted supplementation with CoQ10, NADH, and L-carnitine reduced fatigue severity.
Our approach uses targeted nutritional protocols to reduce the inflammatory load feeding the neuroimmune cycle. Anti-inflammatory dietary interventions, mitochondrial support through NAD+ precursors and CoQ10 from our Action Potential Supplements line, and gut microbiome restoration all address the metabolic underpinning of autonomic failure. This is not supplementation for its own sake. It is treating the substrate that drives microglial activation and T-cell exhaustion.
MSC Therapy and Exosomes: Resetting the Immune Response
The immune dysregulation in POTS and ME/CFS is not subtle. Autoantibodies against adrenergic and muscarinic receptors directly impair autonomic signaling. T-cell exhaustion leaves the immune system unable to clear viral persistence. Hyperactivated mast cells flood tissue with histamine and inflammatory mediators.
Mesenchymal stem cells (MSCs) and their derived exosomes address this at the cellular level. A 2024 review in Cellular and Molecular Neurobiology detailed how MSC-derived exosomes cross the blood-brain barrier and shift microglia from a pro-inflammatory M1 phenotype to the anti-inflammatory M2 state. They suppress T-cell overactivation, promote regulatory T-cell differentiation through IL-10 secretion, and correct Th17/Treg imbalance. A 2025 study in Frontiers in Immunology demonstrated that umbilical cord MSCs reverse abnormal microglial activation by inhibiting the C3a-C3aR complement signaling pathway.
For patients with POTS and ME/CFS, this means MSC-derived exosomes can target the exact mechanisms the Blitshteyn review identifies as pathological: neuroinflammation, autoimmunity, and immune exhaustion. Our Intensive Brain Health Program incorporates MSC therapy and exosomes as part of a protocol that treats the neuroimmune axis directly, not just the symptoms it produces.
What This Means for Patients
The reclassification of POTS and ME/CFS as neuroimmune disorders is not academic. It changes what testing you need, what treatments make sense, and which specialists should be leading your care.
If you are living with POTS, ME/CFS, or Long COVID and your workup stopped at an ECG and a referral to psychiatry, the science says you deserve more. Advanced neuroimaging, autonomic function testing, serum cytokine and autoantibody panels, sleep studies, and nutritional assessment all belong in the diagnostic picture. And treatment should address the neuroimmune mechanism, not mask the symptoms.
At The Neurogenesis Project, this is the workup patients receive because the brain does not fail in one dimension. Autonomic dysfunction, neuroinflammation, immune dysregulation, metabolic compromise, and sleep-disordered breathing are not separate problems. They are nodes in the same network, and treating one while ignoring the others is why conventional approaches fail.
Your brain is the most valuable asset you have. Treating it like one is not optional.